Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1941 (Ipragliflozin) + α-Glucosidase Inhibitor in Japanese T2DM
NCT01242202Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipragliflozin in type 2 diabetes mellitus (T2DM), sponsored by Astellas Pharma. Started Oct 2010; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01242202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01242202.